Division of Nuclear Medicine, Department of Radiology, University of Michigan Health System, University Hospital, Ann Arbor, MI 48109-0028, USA.
Ann Nucl Med. 2011 Aug;25(7):486-93. doi: 10.1007/s12149-011-0492-0. Epub 2011 May 15.
While high-energy gamma and beta probes have gained considerable attention due to their ability to detect cancerous lesions using (18)F-FDG in humans intraoperatively, it is unknown whether the sensitivity of such probes would allow the detection of remaining tumor tissue in the resection bed after removal of macroscopically evident disease.
9L tumors (13 primaries, 17 lymph node metastases) were generated at the upper thigh of Fisher 344 rats. After approximately 2 weeks, microPET was performed to verify increased (18)F-FDG tumor uptake. Tumors were surgically exposed and probe readings of tumor and background tissues were performed in triplicate. To evaluate the ability to detect tiny tumor lesions, 12 tumor fragments (range 0.001-0.032 g) were placed into the resection bed and measured to obtain a tumor-to-muscle ratio (TMR). Lesions were classified as positive if count rates were above 2.5 SD of muscle background. All tumor and muscle tissues were weighed and counted to obtain the "true" tumor-to-muscle background ratio (TMR(counter)) for reference. The presence or absence of tumor tissue was verified by histology.
In the presence of background gamma radiation, the beta probe detected all tumor lesions with TMR greater than 2.5 SD of muscle background (TMR range 1.24-3.9 for all 41 lesions). Despite suitable shielding, lesion identification by the gamma probe was clearly limited by the presence of background radioactivity. As a result, only 11/13 primary tumors, 6/17 lymph nodes and 1/11 tumor fragments were identified above 2.5 SD of muscle background (TMR range 0.64-3.59 for all lesions).
Under experimental conditions, the beta probe was capable to detect minute amounts of tumor tissue at the surface of resection beds. While clinical application of the current beta probe design may depend on the particular intraoperative circumstances including time requirements for surface scanning of resection beds, the data indicate clinical potential for novel designs of hand-held beta probes.
由于高能量的伽马和贝塔探针能够在人体手术中使用(18)F-FDG 检测癌性病变,因此引起了广泛关注,然而,目前尚不清楚这些探针的灵敏度是否能够检测到在切除明显病变后的切除床中残留的肿瘤组织。
在 Fisher 344 大鼠的大腿上部生成了 9L 肿瘤(13 个原发肿瘤,17 个淋巴结转移瘤)。大约 2 周后,进行 microPET 以验证(18)F-FDG 肿瘤摄取增加。将肿瘤暴露并重复进行 3 次肿瘤和背景组织的探针读数。为了评估检测微小肿瘤病变的能力,将 12 个肿瘤碎片(范围 0.001-0.032g)放置到切除床中,并进行测量以获得肿瘤与肌肉的比率(TMR)。如果计数率高于肌肉背景的 2.5 个标准差,则将病变分类为阳性。所有肿瘤和肌肉组织均称重并计数,以获得“真实”的肿瘤与肌肉背景比率(TMR(计数器))作为参考。通过组织学验证肿瘤组织的存在或不存在。
在存在背景伽马辐射的情况下,贝塔探针检测到所有 TMR 大于肌肉背景 2.5 个标准差的肿瘤病变(所有 41 个病变的 TMR 范围为 1.24-3.9)。尽管有适当的屏蔽,但伽马探针的病变识别显然受到背景放射性的限制。结果,仅在 2.5 个肌肉背景标准差以上识别出 13/13 个原发肿瘤、17/17 个淋巴结和 11/11 个肿瘤碎片(所有病变的 TMR 范围为 0.64-3.59)。
在实验条件下,贝塔探针能够检测到切除床表面的微量肿瘤组织。虽然当前贝塔探针设计的临床应用可能取决于特定的术中情况,包括切除床表面扫描的时间要求,但这些数据表明了新型手持式贝塔探针设计的临床潜力。